Measuring the return from pharmaceutical innovation 2012Is R&D earning its investment? |
 |
|
The cohort of companies comprises the 12 publicly-listed companies reporting the highest absolute research and development (R&D) spend for 2008-09. The late stage pipeline includes those compounds which are either in Phase III development or submitted for approval.
Following feedback on the 2011 report, the methodology had been revisited and enhancements and improvements made to a number of elements including the timing of when pipeline information is used for determining revenue forecasts, allocation of R&D cost between development phases and years, and other items which have a minor impact on margins.
These enhancements have also been applied retrospectively, and the 2010 and 2011 results restated, so that findings from prior years are comparable with 2012.
Measuring the return from pharmaceutical innovation 2012
(845.70 KB)
